| Wang, Sanbin |
| Recruiting | 2/3 | 142 | RoW | avatrombopag, Doptelet, Placebo | Peking University People's Hospital, Xiangya Hospital of Central South University, Sichuan Provincial People's Hospital, First Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Xinjiang Medical University, Shanxi Bethune Hospital, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Tang-Du Hospital, The First Affiliated Hospital of Nanchang University | Thrombocytopenia, Stem Cell Transplant Complications | 10/24 | 10/25 | | |
NCT04271644: BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 80 | RoW | BCMA CAR-T cells | Chongqing Precision Biotech Co., Ltd | Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse | 12/23 | 07/24 | | |
NCT04271410: CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma |
|
|
| Recruiting | 1/2 | 80 | RoW | CD19 CAR-T cells | Chongqing Precision Biotech Co., Ltd | Leukemia, Lymphoma, Large B-Cell, Diffuse, Leukemia, B-cell, Lymphoma, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell | 12/23 | 07/24 | | |
NCT04649983: CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma |
|
|
| Recruiting | 1/2 | 40 | RoW | CD19 and CD22 targeted CAR-T cells | Chongqing Precision Biotech Co., Ltd | Leukemia, B-cell, Lymphoma, B-Cell | 12/23 | 07/24 | | |
NCT04265963: CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1/2 | 45 | RoW | CD123 CAR-T cells | Chongqing Precision Biotech Co., Ltd | Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute | 12/23 | 07/24 | | |
NCT04781634: a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL |
|
|
| Recruiting | 1/2 | 40 | RoW | CD19 and CD22 targeted prime CAR-T cells | Chongqing Precision Biotech Co., Ltd | B-ALL | 12/23 | 07/24 | | |
NCT04776330: a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 80 | RoW | BCMA targeted prime CAR-T cells | Chongqing Precision Biotech Co., Ltd | Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse | 12/23 | 07/24 | | |
NCT04782193: a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma |
|
|
| Recruiting | 1/2 | 40 | RoW | CD19 and CD22 targeted prime CAR- T cells | Chongqing Precision Biotech Co., Ltd | B Cell Lymphoma | 12/23 | 07/24 | | |
NCT05654038: A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies |
|
|
| Recruiting | 1/2 | 30 | RoW | Anti-CD19 UCAR-NK cells | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | B-Cell Lymphoblastic Leukemia/Lymphoma | 12/23 | 12/24 | | |
NCT06352281: Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP) |
|
|
| Recruiting | 1/2 | 10 | RoW | CAR-T cells | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | ITP - Immune Thrombocytopenia | 01/26 | 12/27 | | |
| Recruiting | 1/2 | 60 | RoW | Anti-CD19 Autologous CAR-T Cell Infusion, OlyCAR-019 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | B-Cell Leukemia, B-Cell Lymphoma, B-cell Tumors | 06/24 | 06/25 | | |
NCT05748938: A Study of RD14-01 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 12 | RoW | RD14-01, CAR-T infusion | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Solid Tumor | 08/24 | 02/25 | | |
| Recruiting | 1/2 | 20 | RoW | JY231 injection | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Systemic Lupus Erythematosus (SLE) | 09/26 | 12/26 | | |
| Recruiting | 1/2 | 104 | RoW | Venetoclax in combination with azacitidine and CAG, VA-CAG regimen | Hematology department of the 920th hospital | Acute Myeloid Leukemia | 08/24 | 09/24 | | |
| Recruiting | 1/2 | 18 | RoW | Anti-GPRC5D CAR-T cells infusion | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | 02/25 | 12/25 | | |
NCT04877080: CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL |
|
|
| Withdrawn | 1 | 15 | NA | Fast Dual CAR-T Injection | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | B-cell Lymphoma | 06/23 | 12/23 | | |
NCT06210243: C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 1 | 24 | RoW | C752 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Shanghai PerHum Therapeutics Co., Ltd. | Lymphoma, B-Cell, CAR-T | 12/24 | 12/25 | | |
NCT06514768: JY231(JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia(B-ALL) |
|
|
| Recruiting | 1 | 20 | RoW | JY231 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | B-cell Acute Lymphoblastic Leukemia( B-ALL ) | 06/26 | 06/26 | | |
NCT05105867: CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies |
|
|
| Recruiting | 1 | 15 | RoW | Anti-CD19 Universal CAR-T Cells injection | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Gracell Biotechnology Shanghai Co., Ltd., Kunming Hope of Health Hospital | Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B-cell Non-hodgkin Lymphoma | 08/24 | 11/24 | | |
NCT05979792: Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma |
|
|
| Not yet recruiting | 1 | 35 | RoW | CAR-T Therapy | Zhao Weili | Peripheral T Cell Lymphoma | 08/25 | 12/25 | | |
NCT06110208: Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML |
|
|
| Recruiting | 1 | 18 | RoW | CLL1 and CD38 dual-target CAR-T injection | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Gracell Biotechnology Shanghai Co., Ltd. | Acute Myeloid Leukemia | 08/26 | 10/26 | | |
NCT06471478: The Combination of IVIG, Dexamethasone and a Megadose of PBSCs for Decreasing DSAs |
|
|
| Completed | N/A | 11 | RoW | intravenous immunoglobulin, dexamethasone and a megadose of peripheral-blood stem cell transfusion | Hematology department of the 920th hospital | Blood Disease | 10/21 | 08/23 | | |
NCT05015920: A Study Evaluating the Safety and Efficacy of the BD211 Drug Product in β-Thalassemia Major Participants |
|
|
| Recruiting | N/A | 10 | RoW | BD211 Drug Product | Shanghai BDgene Co., Ltd., 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Hematologic Diseases | 02/25 | 02/25 | | |
NCT06515262: Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM |
|
|
| Recruiting | N/A | 10 | RoW | Anti-BCMA-GPRC5D CAR-T cells infusion | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Guangzhou Bio-gene Technology Co., Ltd | Relapsed/Refractory Multiple Myeloma | 11/26 | 12/26 | | |
